The new model was achieved by combining human-induced pluripotent stem cell-derived differentiated cells and primary cell models with the company's proprietary NatLine amplification and maturation platform. According to Human Cell Design, Endoc-BH5 bridges the gap between previous versions and native human pancreatic beta cells. The Endoc-BH cell family, whose first version was released a little over a year ago, has been referenced in more than 100 peer-reviewed publications, the company added.

Diabetes affects more than 500 million people worldwide. As the cellular mechanisms underlying these disorders are not yet fully understood, authentic human beta cell models are key to advancing research and accelerating drug discovery in this area.

Human Cell Design is a French-based biotechnology company providing researchers in industry and academia with unique, physiologically relevant human cell models.

Targeted nanoparticle delivery provides boost for diabetes transplant
Delivering immunosuppressant treatment via targeted nanoparticles could open the door to a long-lasting cure for type 1 diabetes. Transplanting insulin-producing...

Rare disease treatments continue to advance alongside gene therapies
Rare diseases represent an underserved and frequently overlooked area in healthcare. As a result, funding for research in these diseases is often limited....

NIH branch institute launches consortium for pancreatic research
As part of the Impact of Genomic Variation on Function Consortium, researchers at the University of California, San Diego School of Medicine will receive...

NIH awards $2.59M for diabetes gene therapy
Gene therapy technology developer Genprex said that the U.S. National Institutes of Health (NIH) has awarded a $2.59 million grant to the University...